Lung Cancer Canada (LCC) is seeking ROS1 positive non-small cell lung cancer (NSCLC) patients and caregivers who have past or present treatment experience with ENTRECTINIB to share their experiences. This information will be used to provide patient/caregiver input that will help in determining accessibility of this drug for lung cancer patients in Canada. LCC and lung cancer patients appreciate your help with this.
Information can be provided in two ways:
1. Contact Iwo Effiong by email (firstname.lastname@example.org) to schedule a short interview.
2. Provide answers to a few survey questions at https://www.surveymonkey.com/r/W799LRT
Thanks for helping ROS1+ NSCLC patients obtain access to effective targeted therapies worldwide.